{"id":"NCT02398188","sponsor":"Evofem Inc.","briefTitle":"Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)","officialTitle":"A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-09","primaryCompletion":"2015-10-29","completion":"2015-10-29","firstPosted":"2015-03-25","resultsPosted":"2019-01-07","lastUpdate":"2019-01-07"},"enrollment":793,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Central Abdominal Bulging"],"interventions":[{"type":"DRUG","name":"LIPO-202","otherNames":["Salmeterol"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo for LIPO-202"]}],"arms":[{"label":"LIPO-202","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.","primaryOutcome":{"measure":"Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response","timeFrame":"Baseline and End of Study (1 week post last treatment, 9 weeks after first treatment)","effectByArm":[{"arm":"LIPO-202","deltaMin":37,"sd":null},{"arm":"Placebo","deltaMin":48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.397"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":398},"commonTop":["Injection Site Bruising","Injection Site Haemorrhage","Injection Site Pain","Upper Respiratory Tract Infection","Injection Site Erythema"]}}